Previous 10 | Next 10 |
Shares of Harpoon Therapeutics Inc. (NASDAQ:HARP) traded at a new 52-week low today of $9.95. Approximately 159,000 shares have changed hands today, as compared to an average 30-day volume of 503,000 shares. Based on a current price of $10.24, Harpoon Therapeutics Inc. is currently 37.8%...
Cullinan is building a unique hub-and-spoke business model in drug development to build more efficient and scalable pipelines. The company has already built out a pipeline of 7 assets and got the model off the ground to prove that they can structure their pipeline based on opportunist...
Photo by goir/iStock via Getty Images Merus jumps on Citi upgrade Merus (MRUS) shares have climbed ~5.4% in early trading after Citi analyst Yigal Nochomovitz upgraded the stock to buy from neutral. The price target of $31.00 per share implies a premium of ~49.9%. Citing dataset pre...
Three TriTAC clinical programs (HPN424, HPN536 and HPN328) have shown tumor size reductions or stable disease, and meaningful treatment duration All four clinical programs demonstrate half-life extension, target engagement and T cell activation Cytokine release syndrome ob...
Gainers: SemiLEDs (LEDS) +66%.Senseonics (SENS) +49%.Windtree Therapeutics (WINT) +38%.MoSys (MOSY) +34%.Ra Medical Systems (RMED) +29%.LightPath Technologies (LPTH) +27%.American Superconductor (AMSC) +26%.Smart Sand (SND) +25%.The9 (NCTY) +24%.Vinco Ventures (BBIG) +22%....
Gainers: Windtree Therapeutics (WINT) +57%, Senseonics (SENS) +38%, Ra Medical Systems (RMED) +22%, Cullinan Oncology (CGEM) +20%, Progenity (PROG) +10%.Losers: Harpoon Therapeutics (HARP) -25%, Purple Biotech (PPBT) -19%, Adamis Pha...
Harpoon Therapeutics shares fall ([[HARP]] -21.6%) after interim data from its ongoing dose-escalation portion of a Phase 1/2a trial for HPN424 in patients with metastatic castration-resistant prostate cancer ((mCRPC)) failed to impress investors.The ongoing dose escalation Phase 1/2a tr...
The ongoing dose escalation Phase 1/2a trial has enrolled 89 patients with progressive, metastatic castration-resistant prostate cancer in 13 cohorts. Safety data continues to show that HPN424 is generally well tolerated, and cytokine-related adverse events have been transient and...
ASCO is a very important cancer clinical research meeting. We identified 70 smid-cap cancer companies presenting updated clinical data at ASCO21. 13 companies' value increased by over 10% with ASCO21 info release thus far. PDSB is an early ASCO21 mover, with its HPV vaccine ca...
Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calendar for companies due to report. Mond...
News, Short Squeeze, Breakout and More Instantly...
Harpoon Therapeutics Inc. Company Name:
HARP Stock Symbol:
NASDAQ Market:
Harpoon Therapeutics Inc. Website:
Community Bancorp Inc Vermont (CMTV) is expected to report for Q4 2023 CISO Global, Inc (CISO) is expected to report for Q4 2023 TCTM Kids IT Education Inc. (TCTM) is expected to report for quarter end 2023-12-31 Generation Income Properties Inc. (GIPR) is expected to report for quart...
2024-02-14 02:26:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-01-23 08:45:00 ET On Jan. 8, pharmaceutical giant Merck (NYSE: MRK) moved to acquire biotech Harpoon Therapeutics , (NASDAQ: HARP) for $680 million in cash. The point of the acquisition, which should close in the first half of this year, is to gain access to Harpoon's t...